CN102834110B - 使用过氧化物氧化还原酶1(prx1)作为佐剂的方法和组合物 - Google Patents

使用过氧化物氧化还原酶1(prx1)作为佐剂的方法和组合物 Download PDF

Info

Publication number
CN102834110B
CN102834110B CN201080060971.5A CN201080060971A CN102834110B CN 102834110 B CN102834110 B CN 102834110B CN 201080060971 A CN201080060971 A CN 201080060971A CN 102834110 B CN102834110 B CN 102834110B
Authority
CN
China
Prior art keywords
prx1
tlr4
antigen
cells
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201080060971.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN102834110A (zh
Inventor
S·O·戈尔尼克
J·里德尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Health Research Inc
Original Assignee
Health Research Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Health Research Inc filed Critical Health Research Inc
Publication of CN102834110A publication Critical patent/CN102834110A/zh
Application granted granted Critical
Publication of CN102834110B publication Critical patent/CN102834110B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/17—Monocytes; Macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0065—Oxidoreductases (1.) acting on hydrogen peroxide as acceptor (1.11)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y111/00—Oxidoreductases acting on a peroxide as acceptor (1.11)
    • C12Y111/01—Peroxidases (1.11.1)
    • C12Y111/01015—Peroxiredoxin (1.11.1.15)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN201080060971.5A 2009-12-08 2010-12-08 使用过氧化物氧化还原酶1(prx1)作为佐剂的方法和组合物 Expired - Fee Related CN102834110B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26764709P 2009-12-08 2009-12-08
US61/267,647 2009-12-08
PCT/US2010/059411 WO2011071988A1 (en) 2009-12-08 2010-12-08 Methods and compositions using peroxiredoxin 1 (prx1) as an adjuvant

Publications (2)

Publication Number Publication Date
CN102834110A CN102834110A (zh) 2012-12-19
CN102834110B true CN102834110B (zh) 2015-01-14

Family

ID=44145890

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201080060971.5A Expired - Fee Related CN102834110B (zh) 2009-12-08 2010-12-08 使用过氧化物氧化还原酶1(prx1)作为佐剂的方法和组合物

Country Status (7)

Country Link
US (1) US9050291B2 (OSRAM)
EP (1) EP2509623B1 (OSRAM)
KR (1) KR20130028044A (OSRAM)
CN (1) CN102834110B (OSRAM)
CA (1) CA2782132A1 (OSRAM)
IN (1) IN2012DN04875A (OSRAM)
WO (1) WO2011071988A1 (OSRAM)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103468652A (zh) * 2013-07-15 2013-12-25 中国科学院海洋研究所 一种纯化fitc标记的虾白斑综合症病毒（wssv）的方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007089871A2 (en) * 2006-02-01 2007-08-09 The Johns Hopkins University Polypeptide-nucleic acid conjugate for immunoprophylaxis or immunotherapy for neoplastic or infectious disorders

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9612214D0 (en) * 1996-06-11 1996-08-14 Mallinckrodt Veterinary Inc Vaccine
ES2355588T3 (es) * 1997-03-14 2011-03-29 The Children's Hospital Of Philadelphia Composiciones para uso en terapia génica para el tratamiento de hemofilia.
IL125608A0 (en) * 1998-07-30 1999-03-12 Yeda Res & Dev Tumor associated antigen peptides and use of same as anti-tumor vaccines
US6753314B1 (en) * 1999-04-01 2004-06-22 Curagen Corporation Protein-protein complexes and methods of using same
US20020168353A1 (en) * 2001-03-23 2002-11-14 Lynn Ralf Geiben Peroxiredoxin drugs for treatment of HIV-1 infection and methods of use thereof
US20090291087A1 (en) 2002-03-21 2009-11-26 University Of Florida Research Foundation, Inc. Modulating angiogenesis
US20030199464A1 (en) 2002-04-23 2003-10-23 Silviu Itescu Regeneration of endogenous myocardial tissue by induction of neovascularization
US8153410B2 (en) * 2003-07-07 2012-04-10 Fox Chase Cancer Center Alternate morpheein forms of allosteric proteins as a target for the development of bioactive molecules
WO2009059281A1 (en) * 2007-11-02 2009-05-07 Health Research Inc. Compositions and methods for using ca9 protein to stimulate an immune response

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007089871A2 (en) * 2006-02-01 2007-08-09 The Johns Hopkins University Polypeptide-nucleic acid conjugate for immunoprophylaxis or immunotherapy for neoplastic or infectious disorders

Also Published As

Publication number Publication date
CN102834110A (zh) 2012-12-19
EP2509623A4 (en) 2013-06-26
WO2011071988A1 (en) 2011-06-16
IN2012DN04875A (OSRAM) 2015-09-25
US9050291B2 (en) 2015-06-09
EP2509623A1 (en) 2012-10-17
CA2782132A1 (en) 2011-06-16
US20110177129A1 (en) 2011-07-21
EP2509623B1 (en) 2015-03-25
KR20130028044A (ko) 2013-03-18

Similar Documents

Publication Publication Date Title
Murray et al. In situ vaccination with cowpea vs tobacco mosaic virus against melanoma
US12331097B2 (en) T cell receptor constructs and uses thereof
JP2024045573A (ja) 腫瘍特異的なネオ抗原を同定する組成物および方法
Sheng et al. Delivery of antigen using a novel mannosylated dendrimer potentiates immunogenicity in vitro and in vivo
Kottke et al. Induction of hsp70-mediated Th17 autoimmunity can be exploited as immunotherapy for metastatic prostate cancer
CN102215862B (zh) Globo h及含新颖糖脂质佐剂的相关抗癌疫苗
EP2127671B1 (en) Therapeutic agent for cancer
Qin et al. Development of spherical nucleic acids for prostate cancer immunotherapy
KR102679516B1 (ko) 면역원성/치료적 당접합체 조성물 및 그의 용도
US10597731B2 (en) Allogeneic autophagosome-enriched composition for the treatment of disease
Yan et al. Nano-adjuvants and immune agonists promote antitumor immunity of peptide amphiphiles
Llopiz et al. Inhibition of adjuvant-induced TAM receptors potentiates cancer vaccine immunogenicity and therapeutic efficacy
EP2869828B1 (en) Vault immunotherapy
CN110177570A (zh) 包含Sbi蛋白的免疫原性组合物及其用途
US9050291B2 (en) Methods and compositions using peroxiredoxin 1 (PRX1) as an adjuvant
WO2021071468A1 (en) Neoepitope vaccine and immune stimulant combinations and methods
Tang et al. Neoantigens and shared MICB α3 antigen dual-targeted vaccine generates potent antitumor immunity
Jung et al. Yeast-based identification of prostate tumor antigens provides an effective vaccine platform
Li et al. Combinatorial Design of Fatty Acid-Incorporated Plasmid Lipid Nanoparticles Drives Dendritic Cell Hyperactivation for Enhanced Cancer Immunotherapy
EP4633665A2 (en) T cell receptor constructs and uses thereof
WO2026058153A2 (en) Hpv-16 t cell receptor uses and compositions thereof
WO2011071992A1 (en) Inhibition of tumor angiogenesis by inhibition of peroxiredoxin 1 (prx1)
HK40053747A (en) T cell receptor constructs and uses thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20150114

Termination date: 20151208

EXPY Termination of patent right or utility model